Bolt Biotherapeutics (BOLT) vs Immuron (IMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immuron is the larger company by market cap ($8.7 million vs $7.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | IMRN |
|---|---|---|
| Share price | $4.11 | $1.08 |
| Market cap | $7.92M | $8.72M |
| 1-day change | +13.22% | -2.70% |
| EPS (TTM) | $-19.22 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $2.39 |
| 52-week low | $3.10 | $0.677 |
| Distance from 52-week high | -42.92% | -54.81% |
| Analyst consensus | none | none |
| Avg. price target upside | +605.60% | +260.19% |
| Average volume | 26.30K | 2.09M |
| Shares outstanding | 1.93M | 8.07M |
| Employees | 23 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BOLT vs IMRN FAQ
Which is bigger, Bolt Biotherapeutics or Immuron?
Immuron (IMRN) is larger, with a market capitalization of $8.72M compared with $7.92M for Bolt Biotherapeutics (BOLT).
Are Bolt Biotherapeutics and Immuron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.